VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) – Optimi Santé Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness industry, is pleased to announce that its US- OTC listing under the symbol “OPTHF” has received approval from the Depository Trust Company (“DTC”) to make the Company’s common shares eligible for listing. clearing and electronic settlement through DTC (“DTC Eligibility”).

DTC is a subsidiary of the Depository Trust and Clearing Corporation, a US company that manages electronic clearing and settlement of publicly traded companies. DTC eligibility incorporates an electronic method of securities clearing that speeds up receipt of stocks and cash, thereby speeding up the settlement process for some investors. DTC is a member of the United States Federal Reserve, a limited-purpose trust company under New York State banking law and a clearing agency registered with the United States Securities and Exchange Commission.

Optimi further informs that it is about to complete the listing process on the OTCQB exchange operated by OTC Markets Group Inc. Designed for developing and entrepreneurial companies in the United States and abroad, companies must be up-to-date in their financial reports and undergo an annual management audit and certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors with better visibility to improve trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for the analysis and value of securities.

In addition to trading in the United States, Optimi’s common stock continues to trade on the Canadian Stock Exchange under OPTI and on the German Börse Frankfurt (FRA) under 8BN.

Michael Stier, CEO of Optimi, notes: “Today’s announcement is an important step towards expanding our market presence in the United States as we engage with this important shareholder audience. Registration with the OTCQB will provide increased transparency and visibility to the investor community. DTC eligibility provides current and potential Optimi shareholders with a reliable, cost-effective and timely method of clearing and settling our common shares. Overall, today’s news positions Optimi to engage with confidence, determination and consideration in a more meaningful way with current and future investors.

On behalf of the Board of Directors, Optimi Health Corp.

Mike stier
President, CEO and Director


Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to grow, extract, process and distribute high quality functional mushroom products at its two facilities totaling 20,000 square feet nearing completion in Princeton, Colombia. -British. To fully investigate the science of mushrooms, the Company obtained a research exemption under the Food and Drug Regulations (FDR) from Health Canada for the use of psilocybin and psilocin for scientific purposes through its subsidiary. wholly owned Optimi Labs Inc. Optimi has also applied for a distributor’s license under the Canadian Narcotic Control Regulations governing the possession, distribution, sale, laboratory analysis and research and development of psilocybin formulations and of psilocin. Optimi is committed to expertly cultivating and producing quality production subject to and in accordance with the conditions of all applicable laws and regulations in order to ensure safe and superior Canadian mushroom production.

Learn more about:

Investor Relations
E-mail: [email protected]é.ca
Telephone: +1 (778) 930-1321
The Web:


This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. All statements that express or involve discussions regarding expectations, beliefs, plans, goals, assumptions or future events or performance (often, but not always, through the use of words or phrases such as ” will likely result “,” are expected “,” expects “,” will continue “,” is expected “,” anticipates “,” believes “,” estimates “,” intends “,” plans “, “Forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results differ materially from those expressed in these forward-looking statements. No assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this press release should not be improperly relied upon. These statements ations speak only as of the date of this press release. In particular and without limitation, this press release contains forward-looking statements relating to the distributor’s license application, the activities proposed to be carried out under the Company’s research exemption and the associated activities related to the psilocybin and psilocin and to Optimi’s plans, priorities and goals.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the control of Optimi, which could cause actual results and events to occur. differ materially from those disclosed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set out in the “Forward-Looking Statements” and “Risk Factors” in the Company’s final prospectus. dated February 12, 2021. Optimi assumes no obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each of these factors or the extent to which one factor, or a combination of factors, may make a difference. so that the results differ materially from those contained in any forward-looking statement. press release are expressly qualified in their entirety by this disclaimer.

The CSE accepts no responsibility for the adequacy or accuracy of this release.